Sonic hedgehog (Shh) signaling plays a crucial role in the normal development of many tissues including the hair follicle;however, inappropriate pathway activity is associated with a variety of human birth defects, and up to 25% of human cancers, including cutaneous basal cell carcinomas (BCCs). Human tumors induce hedgehog signaling differently: cell autonomous pathway activation, autocrine stimulation, or paracrine stimulation via the surrounding stroma. Each type of cancer requires the pathway for growth, but differs in the cellular origin of those growth signals, highlighting the emerging need to identify new therapeutic targets and fill gaps in understanding the signaling interactions between tumor and stroma. The goal of ARO46786, now in its 10th year, is to focus on gaps in our understanding of hedgehog signaling during regeneration and tumor formation in order to develop new therapeutic leads. Each of the three aims addresses a particular gap that this project will investigate over the next funding period as we aim to : 1) Determine the role of Polarity Protein signaling in hedgehog signaling by determining epistatic relationships of aPKC in ciliogenesis, determining how aPKC regulates hedgehog signaling, determining aPKC and PI3 kinase crosstalk in the control of hedgehog pathway, and determining the activity of aPKC regulators on BCCs in vitro and in vivo;2) Functionally dissect the hedgehog paracrine signaling network by defining the function of Sox2 and Sox18 in hair regeneration, defining the genetic relationship between Gli, Sox, and noggin, and determining whether Gli and Sox directly regulate gene expression;3) Elucidate novel mechanisms underlying invasive BCCs by confirming mutation breakpoint and altered expression, determining cellular requirements for BCC tumor formation, and identifying the mechanisms of Smo inhibitor resistance in BCCs.

Public Health Relevance

Sonic hedgehog (Shh) signaling plays a crucial role in the normal development of many tissues including the hair follicle;however, inappropriate pathway activity is associated with a variety of human birth defects, and up to 25% of human cancers, including cutaneous basal cell carcinomas (BCCs). The goal of this proposal is to focus on gaps in our understanding of hedgehog signaling during regeneration and tumor formation in order to develop new therapeutic leads by determining the role of Polarity protein signaling in the hedgehog pathway, functionally dissecting the hedgehog paracrine signaling network, and by elucidating the novel mechanisms underlying invasive BCCs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
2R01AR046786-11A1
Application #
8317092
Study Section
Special Emphasis Panel (ZRG1-MOSS-C (90))
Program Officer
Baker, Carl
Project Start
2000-04-17
Project End
2017-03-31
Budget Start
2012-05-01
Budget End
2013-03-31
Support Year
11
Fiscal Year
2012
Total Cost
$359,820
Indirect Cost
$134,820
Name
Stanford University
Department
Dermatology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442
Whitson, Ramon J; Lee, Alex; Urman, Nicole M et al. (2018) Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas. Nat Med 24:271-281
Whitson, Ramon J; Oro, Anthony E (2017) Soil Primes the Seed: Epigenetic Landscape Drives Tumor Behavior. Cell Stem Cell 20:149-150
Mirza, Amar N; Fry, Micah A; Urman, Nicole M et al. (2017) Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment. JCI Insight 2:
Wang, Kevin; Lee, Carolyn S; Marinkovich, M Peter et al. (2016) Factors That May Promote an Effective Local Research Environment. J Invest Dermatol 136:1529-1531
Kwon, Gina P; Ally, Mina Sarah; Bailey-Healy, Irene et al. (2016) Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC). J Am Acad Dermatol 75:213-5
Danial, Christina; Sarin, Kavita Y; Oro, Anthony E et al. (2016) An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Clin Cancer Res 22:1325-9
Urman, Nicole M; Mirza, Amar; Atwood, Scott X et al. (2016) Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions. PLoS One 11:e0168031
Ally, Mina S; Ransohoff, Katherine; Sarin, Kavita et al. (2016) Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatol 152:452-6
Atwood, Scott X; Sarin, Kavita Y; Li, Jiang R et al. (2015) Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma. J Invest Dermatol 135:2138-2141

Showing the most recent 10 out of 39 publications